← Eichor
Study identifier: NCT03193541 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

A Novel Multiplex ELISA Assay for Evaluating Patients With Microscopic Hematuria for Bladder Cancer

Condition: Bladder Cancer  ·  Sponsor: Cedars-Sinai Medical Center

PhaseN/A
Planned participants900
Who can joinAll sexes, 18 Years to 90 Years
Healthy volunteersNo

About this study

To improve upon the non-invasive detection of BCa by further validating a multiplex ELISA assay directed at a BCa-associated diagnostic signature in voided urine samples of patients with microscopic hematuria.

This description comes directly from the study's public registry record.

Talk to the study team

Charles Rosser, MD  ·  310-423-5609  ·  charles.rosser@cshs.org

Always discuss trial participation with your own doctor first.

Locations (8)

VA Long Beach Healthcare SystemLong Beach, California, United StatesRecruiting
Cedars-Sinai Medical CenterLos Angeles, California, United StatesRecruiting
UCLA Medical CenterLos Angeles, California, United StatesRecruiting
Hoag Memorial Hospital PresbyterianNewport Beach, California, United StatesRecruiting
University of Rochester Medical CenterRochester, New York, United StatesRecruiting
UT Southwestern Medical Center at DallasDallas, Texas, United StatesRecruiting
Nara Prefecture Seiwa Medical CenterNara, Nara, JapanRecruiting
Nara Medical UniversityNara, JapanRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT03193541